Advertisement Pharmaceutical Business review - Page 5 of 5282 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 21, 2026

EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.

The PRIME designation aims to provide additional regulatory support and guidance for medicines. Credit: afotostock / Shutterstock.com.